4 recruiting, 3 unknown, 1 completed, 1 not yet recruiting. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Unknown 3, Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Newly Diagnosed: new trials by email Literature Review of Newly Diagnosed trials Research Report on Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? CAR-T, ASCT - Multiple Myeloma, Newly Diagnosed | Phase 2 | Not yet recruiting | Xuzhou Medical University | 60 | 2025-07-15 | 2025-07-17 |
| Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia VACl, VACh, VACl Alternating With VACh - Acute Myeloid Leukemia, Adult, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 172 | 2024-07-29 | 2025-11-19 |
| Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma Zanubrutinib combined with Obinutuzumab - Follicular Lymphoma, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 39 | 2024-03-31 | 2024-09-03 |
| Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma XPO1 inhibitor - nk/T-cell Lymphoma, Newly Diagnosed | Phase 2 | Recruiting | Chinese PLA General Hospital | 10 | 2023-05-01 | 2023-04-27 |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, Zanubrutinib, bendamustine, rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 63 | 2022-03-22 | 2022-03-31 |
| Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Chidamide, Azacitidine, Venetoclax - Acute Monocytic Leukemia, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 92 | 2022-03-01 | 2025-11-21 |
| Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML Cladribine Injection, Aclarubicin, G-CSF - Acute Myeloid Leukemia, Elderly Patients | Phase 2 | Unknown | Sun Yat-sen University | 34 | 2021-03-01 | 2020-12-17 |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL Ponatinib 15 MG Oral Tablet - Acute Lymphoblastic Leukemia, Adult, Ph+ ALL | Phase 2 | Terminated | Institute of Hematology and Blood Transfusion, Czech Republic | 4 | 2021-02-16 | 2024-08-14 |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2020-09-25 | 2023-06-18 |
| Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) Blinatumomab - Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL | Phase 2 | Completed | Institute of Hematology and Blood Transfusion, Czech Republic | 27 | 2019-05-09 | 2024-04-04 |
Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Monocytic, Acute (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Hemic and Lymphatic Diseases (8) · Hematologic Diseases (7) · Leukemia (6) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphoproliferative Disorders (5) · Lymphatic Diseases (4) · Leukemia, Lymphoid (3) · Leukemia, Myeloid (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
Aclarubicin (1) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Bortezomib (1) · Cladribine (1) · Cyclophosphamide (1) · Cytarabine (1) · Dexamethasone (1) · Granulocyte Colony-Stimulating Factor (1) · Lenalidomide (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Rituximab (1) · Tablets (1) · blinatumomab (1) · dexamethasone acetate (1)
Institute of Hematology and Blood Transfusion, Czech Republic (2) · Sun Yat-sen University (2) · The First Affiliated Hospital of Soochow University (2) · Chinese PLA General Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · The First Affiliated Hospital of Xiamen University (1) · Xuzhou Medical University (1)
China (7) · Czechia (2)
Cyril Salek, MD (2) · Bing Xu (1) · Hua Wang, MD. (1) · Kailin Xu (1) · Sai Huang, Graduate (1) · Sheng-Li Xue, M.D. (1) · Shuhua Yi (1) · Yu Zhao, Graduate (1)
PMID 22331940, PMID 25878120, PMID 26432046, PMID 27347812, PMID 27505637, PMID 28911074, PMID 31208944, PMID 32972802